Covid19 Clinical Trial
Official title:
RRisk Factors Worsening COVID19 (Coronavirus Infectious Disease 2019) for Outpatient With Home Monitoring (COVID-A-DOMEVA Study)
The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the
COVID-19 (risk or protective factors), in out-patients suspected of being infected with
precocious home monitoring.
The primary event defining the aggravation will be then: hospitalization (medicine,
resuscitation) or death.
The studied potential risk factors will be mainly:
- Socio-demographic: age, sex, place of residence or income
- Comorbidities
- Clinical signs: asthenia, dyspnea (kinetics)…
- Drugs other than those related to the infection
For this research project, this study needs to use the patient's data of the COVIDADOM cohort
(patients suspected of being infected with SARS-CoV-2 with home monitoring) and will collect
some supplementary data (clinical and biological). All these data will be integrated and
analyzed in the PREDIMED clinical data lake platform (The implementation of PREDIMED has been
approved by the French authority in terms of GDPR, CNIL, on October 10, 2019).
In front of the recent emergence of the SARS-CoV-2 coronavirus (COVID) in December 2019 in
the Wuhan region of China, knowledge of the clinical course and of the aggravating risk
factors linked to this virus is still incomplete.
COVID is associated with severe morbidity and an estimated mortality of 2-4% in patients
without comorbidity. According to a WHO report published on the situation in China, patients
with serious chronic pathologies, such as diabetes or severe obesity, are particularly
vulnerable and mortality rates were higher: from 7 to 13%.
Monitoring and describing the clinical pathway of out-patients suspected of being infected
according to their medical history should improve knowledge of COVID, and then adapt patient
care management and control the COVID pandemic.
Currently, few European studies have described the potential risk factors that could lead to
the worsening of the disease. Since the March 16th, the university hospital of Grenoble
(France) has developed an information technology system to monitor out-patients suspected of
being infected with SARS-CoV-2 coronavirus and with early home monitoring: the COVIDADOM
cohort
That's why the COVIDADOMEVA study is then to identify the risk factors aggravating the COVID,
in out-patients with precocious home monitoring.
The primary event defining the aggravation will be then: hospitalization (medicine,
resuscitation) or death
The studied potential risk factors will be the following:
- Socio-demographic: age, sex, place of residence, CSP, and income.
- Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure,
diabetes imbalance, etc.
- Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight
gain…
- Drugs other than those related to the infection and potential self-medication
(anti-inflammatory, CEI, ARA…)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |